Abstract
Tourette Syndrome (TS) is a childhood-onset neurodevelopmental disorder of complex genetic architecture, characterized by multiple motor tics and at least one vocal tic persisting for more than one year. We performed a genome-wide meta-analysis integrating a novel TS cohort with previously published data, resulting in a sample size of 6,133 TS individuals and 13,565 ancestry-matched controls. We identified a genome-wide significant locus on chromosome 5q15 and one array-wide significant locus on chromosome 2q24.2. Integration of eQTL, Hi-C and GWAS data implicated the NR2F1 gene and associated lncRNAs within the 5q15 locus, and the RBMS1 gene within the 2q24.2 locus. Polygenic risk scoring using previous GWAS results demonstrated statistically significant ability to predict TS status in the novel cohort. Heritability partitioning identified statistically significant enrichment in brain tissue histone marks, while polygenic risk scoring on brain volume data identified statistically significant associations with right and left putamen volumes. Our work presents novel insights in the neurobiology of TS opening up new directions for future studies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the EMTICS (FP7-HEALTH, Grant agreement ID: 278367), TSEUROTRAIN (FP7-PEOPLE, Grant agreement ID: 316978), and NINDS (1R01NS105746-01A1) grants. AJW was funded by R01NS105746, the Tourette Association of America, and the Weill Institute for Neurosciences. AM was funded by the Deutsche Forschungsgemeinschaft (DFG; FOR 2698). AS received support from the NIHR UCL/H Biomedical Research Centre. BH is an employee of Boehringer Ingelheim Pharma. CJ was funded by Lundbeck Fonden, grant number R100-2011-9332. CB was supported by funding from the Merit-prize fellowship of Semmelweis University, the Bolyai Janos research fellowship of the Hungarian Academy of Sciences BO/00987/16/5, the UNKP-18-4 of the new National Excellence Program of the Ministry of Human Capacities and the Baron Munchausen Program of the Institute of Medical Chemistry, Molecular Biology and Pathobiochemistry, Semmelweis University. DCC was funded by the TSAA, by the Stichting VC-GGZ, and by TS-EUROTRAIN. DM has received research support from Ipsen Corporate and funding grants from Dystonia Medical Research Foundation Canada, Parkinson Canada, The Owerko Foundation, and the Michael P Smith Family. LKD was supported by grants from the National Institutes of Health including R01NS102371 and R01NS105746. PM has received grants from the Spanish Ministry of Science and Innovation [RTC2019-007150-1], the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER), PI16/01575, PI19/01576], the Consejeria de Economia, Innovacion, Ciencia y Empleo de la Junta de Andalucia [CVI-02526, CTS-7685], the Consejeria de Salud y Bienestar Social de la Junta de Andalucia, PE-0210-2018]. PJ and CZ were funded by the National Science Center, Poland: UMO-2016/23/B/NZ2/03030. ZT funded by Lundbeck Fonden, grant number R100-2011-9332. TIC Genetics was supported by grants from NIH (MH115958, MH115960, MH115962, MH115961, MH115993, MH115963, MH115959) and the New Jersey Center for Tourette Syndrome and Associated Disorders (NJCTS).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was ruled as exempt category 4 (secondary research of non-identifiable data) by the Purdue University IRB
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Summary statistics available online.
